Health Care & Life Sciences » Biotechnology | Audentes Therapeutics Inc.

Audentes Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
12,996.00
60,500.00
95,957.00
105,613.00
133,695.00
414,307
Other Current Assets
151.00
441.00
1,382.00
2,824.00
3,315.00
5,465
Total Current Assets
13,147.00
60,941.00
97,339.00
108,437.00
137,010.00
419,772
Net Property, Plant & Equipment
110.00
264.00
2,968.00
18,936.00
24,372.00
32,099
Total Investments and Advances
-
1,698.00
2,930.00
3,020.00
3,604.00
3,748
Intangible Assets
-
-
11,631.00
11,631.00
11,631.00
11,631
Other Assets
70.00
106.00
2,601.00
33.00
2,045.00
5,305
Total Assets
13,327.00
63,009.00
117,469.00
143,269.00
181,218.00
475,176
ST Debt & Current Portion LT Debt
-
-
107.00
-
-
Other Current Liabilities
386.00
3,111.00
7,616.00
12,560.00
17,712.00
Total Current Liabilities
386.00
3,111.00
7,723.00
12,560.00
17,712.00
Long-Term Debt
-
-
44.00
-
-
Provision for Risks & Charges
-
-
4,414.00
5,089.00
743.00
Deferred Taxes
-
-
3,260.00
3,260.00
1,014.00
Other Liabilities
29.00
34.00
339.00
1,777.00
2,595.00
Total Liabilities
415.00
3,145.00
15,780.00
23,898.00
24,620.00
Common Equity (Total)
2,225.00
12,539.00
34,061.00
119,371.00
156,598.00
Total Shareholders' Equity
12,912.00
59,864.00
101,689.00
119,371.00
156,598.00
Total Equity
12,912.00
59,864.00
101,689.00
119,371.00
156,598.00
Liabilities & Shareholders' Equity
13,327.00
63,009.00
117,469.00
143,269.00
181,218.00
Preferred Stock (Carrying Value)
15,137.00
72,403.00
135,750.00
-
-

About Audentes Therapeutics

View Profile
Address
600 California Street
San Francisco California 94108
United States
Employees -
Website http://www.audentestx.com
Updated 07/08/2019
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R.